Skip to content

Generative design and computational characterization of pyrazoline-based EGFR kinase inhibitor candidates.

Oct 2026 · Journal of Molecular Graphics and Modelling · Vol 150, pp. 109631 · 0 citations · 40 references
Medicine

TL;DR

Structural-activity analysis based on the predicted binding modes suggests that hinge-directed hydrogen bonding to Met793 and π-π stacking with Phe856 are the principal determinants of predicted affinity, modulated by substituent electronics and steric bulk at the R, R1, and R2 positions.

Abstract

The epidermal growth factor receptor (EGFR) is an established therapeutic target in breast, colorectal, and non-small cell lung cancers, and pyrazoline-containing scaffolds have been repeatedly reported as EGFR inhibitors. This study combined generative machine learning with physics-based modelling to design and computationally characterize novel pyrazoline analogues targeting the EGFR kinase ATP-binding site. A curated set of 50 experimentally validated pyrazoline-based EGFR inhibitors, compiled from ChEMBL and the primary literature, was used to seed the Mol2Mol model in REINVENT4, generating a large library of structurally related analogues. The library was sequentially filtered according to Tanimoto similarity to the seed actives (≥0.6), predicted physicochemical, pharmacokinetic, and toxicity properties, synthetic accessibility (SA score <6), and molecular docking against the EGFR kinase domain (PDB 5U8L), using a self-docking validated protocol (redocking RMSD 1.342 Å). Five candidates, designated PyEG1-PyEG5, achieved docking scores between -9.5 and -10.6 kcal/mol, better than the redocked native ligand (-9.2 kcal/mol). All five complexes remained stable during 100 ns molecular dynamics simulations, with backbone RMSD ≤ 0.27 nm, average ligand RMSD ≤ 0.18 nm, and radii of gyration close to those of the reference complex. MM-GBSA end-point calculations yielded binding free energies of -9.9 to -37.5 kcal/mol, with PyEG5 (-37.5 ± 2.5 kcal/mol) approaching the reference ligand value (-37.6 ± 6.0 kcal/mol). Density functional theory calculations (B3LYP/6-31G(d)) indicated HOMO-LUMO gaps of 5.89-6.65 eV, with PyEG2 and PyEG5 predicted to be the most reactive and PyEG3 the most kinetically stable. Structure-activity analysis based on the predicted binding modes suggests that hinge-directed hydrogen bonding to Met793 and π-π stacking with Phe856 are the principal determinants of predicted affinity, modulated by substituent electronics and steric bulk at the R, R1, and R2 positions. These findings are entirely computational; PyEG1-PyEG5 should be considered prioritized synthetic targets, and their activity requires confirmation through biochemical kinase assays and cell-based testing.

View source

Similar papers

Oct 2026

Discovery and Mechanistic Investigation of a Novel Kinase Inhibitor Targeting EGFR Resistance Mutations.

BACKGROUND The Epidermal Growth Factor Receptor (EGFR) serves as a core target in tumor-targeted therapy. Mutations in EGFR frequently lead to resistance against clinical Tyrosine Kinase Inhibitors (TKIs), underscoring the critical need to develop novel EGFR-targeting compounds for overcoming drug resistance. METHODS...

Lu Qi, Shu-Ping Chen, Ying Zhang · 0 citations
Oct 2026

Pharmacophore modelling-based screening of natural allosteric EGFR inhibitors using molecular docking, DFT, and molecular dynamics simulations.

The development of allosteric inhibitors is a promising strategy for targeting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), especially in cases where orthosteric inhibitors face resistance. However, despite their selective inhibition of EGFR mutations, fourth-generation allos...

Fatima Munir, M. Amir, Kashif Hussain et al. · 0 citations
Sep 2026

Ligand-based pharmacophore modeling and molecular dynamics driven discovery of novel MEK1 inhibitors targeting KRAS signalling pathway.

The KRAS oncogene, which plays a crucial role in numerous human malignancies, remains a significant challenge. It is amongst the most mutated oncogenes within human cancers, specifically in pancreatic, colorectal, and non-small cell lung cancers, where it is a key driver of cancer initiation and growth. Despite its imp...

Krishna Kalaskar, R. Alavala · 0 citations
#artificial intelligence Review Open access Sep 2026

Generative AI for Drug Discovery: GPT-2 and LSTM-Based Models for Designing EGFR Inhibitors

This work creates new EGFR inhibitors using generative artificial intelligence (AI) by fine-tuning a GPT-2 model on a dataset comprising around 500,000 molecules from the ChEMBL database by showing the synergy between AI and in silico drug design.

Omar Dasser, Othman Filali Benaceur, Salma Fadel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.